The FDA has accepted an investigational new drug application for Editas Medicine’s experimental CRISPR genome editing medicine for the treatment of Leber congenital amaurosis type 10, the company announced in a press release.
EDIT-101 is administered as a subretinal injection to deliver gene editing machinery to photoreceptor cells.
“The FDA’s acceptance of our IND for EDIT-101 is a significant moment in the field of genome editing, and importantly, a critical milestone for patients, as we are now one step closer to a treatment for LCA10,” Editas President and CEO
Uncategorized